Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.61
Nov 20 • 3:59 PM ET Dollar change-0.23 Percentage change(-8.10%)
Aftermarket Close
2.61
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
28.37M
Enterprise Value
24.59M
Income
1.91M
Sales
21.58M
Book/sh
1.15
Cash/sh
0.42
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
36
IPO
Sep 21, 2004
P/E
15.20
Forward P/E
9.67
PEG
0.22
P/S
1.31
P/B
2.26
P/C
6.24
P/FCF
17.19
EV/EBITDA
12.61
EV/Sales
1.14
Quick Ratio
3.45
Current Ratio
5.50
Debt/Eq
0.06
LT Debt/Eq
0.03
Option/Short
No / Yes
EPS (ttm)
0.17
EPS next Y
0.27
EPS next Q
0.02
EPS this Y
69.70%
EPS next Y
44.64%
EPS next 5Y
44.22%
EPS past 3/5Y
- -
Sales past 3/5Y
23.50% 17.02%
EPS Y/Y TTM
26.09%
Sales Y/Y TTM
20.36%
EPS Q/Q
49.84%
Sales Q/Q
18.01%
Insider Own
19.47%
Insider Trans
0.36%
Inst Own
22.68%
Inst Trans
-40.31%
ROA
13.39%
ROE
16.95%
ROIC
14.82%
Gross Margin
60.00%
Oper. Margin
8.48%
Profit Margin
8.86%
SMA20
-16.05%
SMA50
-25.93%
SMA200
-26.72%
Trades
Shs Outstand
10.87M
Shs Float
8.75M
52W High
6.42 -59.35%
52W Low
2.66 -1.99%
Volatility
6.66% 7.74%
ATR (14)
0.24
RSI (14)
32.58
Beta
1.75
Rel Volume
1.02
Avg Volume
49.07K
Volume
50,237
Perf Week
-14.43%
Perf Month
-25.85%
Perf Quarter
-40.82%
Perf Half Y
-24.78%
Perf YTD
-46.52%
Perf Year
-46.95%
Perf 3Y
24.58%
Perf 5Y
-64.82%
Perf 10Y
-3.33%
Prev Close
2.84
Price
2.61
Change %
-8.10%
Consensus
Buy
Avg. Price Target
$6.08
Implied Upside
+133.0%
Analysts2incl. previous ratings
Rating Distribution1 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 17, 2026Initiated
NNorthland Capital
Market Perform$4+53.3%
Jan 26, 2021Initiated
RILY logoRB. Riley Securities
Buy$12.50+378.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amron Arthur HDirectorNov 16 '26Buy3.005,00014,975167,137Nov 18 04:57 PM
Amron Arthur HDirectorNov 17 '26Buy2.842,5007,100169,637Nov 18 04:57 PM
WEXFORD CAPITAL LP10% OwnerAug 18 '26Option Exercise3.608122,92356,872Aug 20 04:14 PM
Banks Robert R. Jr.President and CEOMar 23 '26Option Exercise1.44120,000172,800190,000Mar 25 04:54 PM
Krandel JudyChief Financial OfficerMar 23 '26Option Exercise1.7168,861117,75268,861Mar 25 04:53 PM
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
PresidentMr. Robert Banks
Chief Financial OfficerMs. Judy F. Krandel C.F.A.
Director of BrandBrianne McGuire
Vice President of QualityVashone R. Thomas
President of Aether Water SystemsMr. Greg Lucas